| The Whole Truth
Covid-19 Covid-19 Vaccines Professor Jean-Bernard Fourtillan Doctor Christian Tal Schaller Doctor Serge Rader Frédéric Chaumont August 20, 2020 |
The calamities of the Vaccine they want to inject in your body
4 fragments of HIV1 which give to
vaccinated people: AIDS syndrom and
Immunodeficiency as a consequence
DNA sequences from the malaria germ which
give Malaria to vaccinated people
157 additional DNA and protein sequences
(see Patent US 8,243,718 B2), whose presence
and role are unexplained
Nanoparticles which will allow definitive
control of people vaccinated thanks to 5G
The ChAdOx1 n-CoV-19 vaccine they want to inject in your body contains
ChAdOx1 n-CoV-19: C ovid-19 coronavirus carried by th e vecto r v irus ChAdOx1
Nanoparticles described in Microsoft Patent PCT/ U S201 9/ 038084 ,wh ich
will c ontrol you t hanks t o 5 G
Disinfectant : s: either T himerosal
or Formaldehyde
and antibiotics
COVID-19 is an artificial coronavirus made in France by the Institut Pasteur from natural Sars-CoV coronavirus
Covid-19 is the result of several genetic manipulations of a strain of Coronavirus Sars-CoV, associated with severe acute respiratory syndrome (SARS), resulting from a sample listed under the number 031589, collected from bronchoalveolar washings of Sars infected patients by scientists of Institut Pasteur, before 2003, at the French hospital in Hanoi (Vietnam)
– 1st Step: Sars-CoV-1 was pr oduced b ya first patent (2003: European Patent E P1 69 48 29 B1 and US Patent US 012.8224 A1) from Sars-CoV collected in Hanoi before 2 003 – 2nd Step: Sars-CoV-2 was a continuation of the first US patent US 012.8224 A1, p rotected by the second US Patent US 8,243,718 B2 (2011), from Sars-CoV-1 – 3rd Step: Covid-19 was produced from Sars-Cov-2 by inserting into its genome 4 sequences of HIV1 (RNA AIDS virus)
Finally
Covid-19 was made in France by French scientists at the Institut Pasteur from natural Sars-CoV, then transferred to Wuhan where the People of Institut Pasteur released it, unbeknownst to scientists in the Wuhan laboratory and the Chinese government
When she says: “Covid-19 is not a Chinese virus”, CHINA DOES NOT LIE!
Doctor Frédéric Tangy is the father of the Covid-19
Doctor Frédéric Tangy
Director of Vaccine Innovation at the Institut Pasteur
Publications related to coronaviruses and vaccines
1- 2003: Inventor in Patents EP 1 694 829 B1 and US 012.8224 A1
2- 2005: Publication: Frédéric TANGY and Hussein Y. Naim.Live Attenuated Measles Vaccine as a Potential Multivalent Pediatric Vaccination Vector.
VIRAL IMMUNOLOGY, Volume 18, Number 2, 2005, page 317-326 3- 2011: Inventor in Patent US 8,343,718 B2
See Document 2
4- 2014: Publication: Nicolas Escriou, ,Benoît Callendret, Valérie Lorin, Chantal Combredet, Philippe Marianneau, Michèle Février, Frédéric Tangy. Protection contre le coronavirus du SRAS conférée par le vaccin vivant contre la rougeole exprimant la glycoprotéine de pointe.
Virology, Volumes 452–453, March 2014, page 32-41
5- 2020: Paris-Match article from April 9-15, 2020
6- 2020: Paris-Match article from May 14-20, 2020
From Sars-CoV to Covid-19
Sars-CoV
Collected, before 2003, at French hospital of Hanoi, by Institut Pasteur (sample n° 031589)
1st Patent in 2003 Patent EP 1 694 829 B1 Patent US 012.8224 A1
1 DNA sequence of 29746 nucleotides + 157 DNA and PRT sequences inserted into RNA genome of Sars-CoV
Sars-CoV1 Frédéric Tangy
2nd Patent in 2011 Patent US 8,243,718 B2
CONTINUATION OF Patent EP 1 694 829 B1 Patent US 012.8224 A1
Sars-CoV2 Frédéric Tangy
3rd Patent in 2019
Patent filed in 2019
International Publication date in 2021
Insertion of 4 fragments of HIV1, corresponding to short segments of amino acids found in
the gp 120 and the Gag of HIV1, in the Sars-CoV2 genome
Covid-19
Frédéric Tangy
Covid-19: an artificial virus made in France
First Patent US 2007/0128224 A1
Patent US 2007/0128224 A1
Claims 1
Patent US 8,243,718 B2 continuation of First Patent US 2007/012.8224 A1
From Covid-19 to ChAdOx1 n-CoV-19 Vaccine Covid-19
Insertion of Covid-19 genome into the genome of a viral vector
(ChAdOx1 C himpanzee DNA a denovirus)
Jenner
Institute
Adrian Hill
Director of Jenner Institute
Covid-19 vaccine
ChAdOx1 nCoV-19 (AstraZeneca, Sanofi)
Insertion of tracing nanoparticles
in the vaccine vial to be injected into the human body
together with the vaccine
US Patent WO 2020/060606 A1 PCT/US20 19/038084 Microsoft
Final vaccine
Bill G ates
Nanoparticles they want to inject in your body together with ChAdOx1 nCovid-19 Vaccine
Satellites for 5G
Task server
Nanoparticles 5G relays
injected
together with vaccine
Vaccinated people
Nanoparticles
Mobile phones
Bill Gates
Thrombinoscope of the promoters of the ChAdOx1 nCoV-19 vaccine
Bill Gates and his allies
Bill Gates Emmanuel Macron Jacques Attali Agnès Buzyn Yves Lévy Olivier Véran
Jérôme Salomon Dominique Martin Tedros Adhanom
Anthony Fauci Frédéric Tangy Adrian Hill
Ghebreyesus
WARNING
– Covid-19 helped spark a false pandemic, and spread fear across the world, to make us accept the Covid-19 vaccine.
– By seeking to vaccinate the entire world population, the sponsors of this vaccine, Bill Gates and his allies, want to enslave and control us, pursuing two objectives:
– Control the entire world population after having vaccinated it, thanks to the deployment of 5G; – Limit the world’s population.
This vaccine is very dangerous because it will cause, i n vaccinated people, deleterious immunodeficiency, due, i n particular, t o the presence, in its genome, of 4 RNA fragments from HIV, th e AIDS virus, and, moreover, DNA fragments from the malaria germ.
MEN WORLDWIDE MUST REFUSE COVID-19 VACCINE THAT BILL GATES AND ITS ALLIES WANT TO IMPOSE ON US
We invite all people
who consider information
of this video as Fake-News
to check their accuracy
on the links provided under this video
Data Sources of Information for the Truth about Covid-19 and ChAdOx1 nCoV-19 Vaccine are presented in the attached PDF below
PRELUDE
To fully control and enslave the world’s population, by monitoring and weakening it, the leaders of the New World Order had nothing better at their disposal than a Vaccine. With this diabolical intention, they had many genetic manipulations carried out, on the genome of the Sars-CoV coronavirus responsible for the SARS epidemic that occurred between 2002 and 2003 in Asia.
The Covid-19 coronavirus, different from Sars-CoV2, is an artificial virus that is the result of many genetic manipulations carried out on the natural Sars-CoV coronavirus, which successively led to 3 artificial coronaviruses Sars-CoV1, Sars CoV2, and Covid-19, described in 3 patents filed by the Institut Pasteur, which provide their intellectual protections
In its genome, Covid-19 carries, among other calamities, 4 RNA fragments from HIV, the AIDS virus, which corresponds to short segments of amino acids found in gp120 and Gag of HIV-1, which will place all vaccinated people in immunodeficiency, and DNA fragments from the malaria germ.
Men around the world must open their eyes and understand that the natural Sars-CoV coronavirus poses no danger to humanity, unlike artificial Covid-19. Covid-19 helped spark a false pandemic, and spread fear across the world, to make us accept the Covid-19 vaccines.
Numerical tracing nanoparticles have been added to the vials of the final Covid-19 vaccine (ChAdOx1 nCoV-19).
By seeking to vaccinate the entire world population, the promoters of the Covid-19 vaccines pursue two objectives:
– Control the entire world population after having vaccinated it, thanks to the deployment of 5G, because these vaccines contain nanoparticles which will allow the identification and permanent control of vaccinated individuals; – Limit the world’s population.
| From Sars-CoV
to Covid-19 |
Doctor Frédéric Tangy is the father of the Covid-19
Doctor Frédéric Tangy
Director of Vaccine Innovation at the Institut Pasteur
Publications related to coronaviruses and vaccines
1- 2003: Inventor in Patents EP 1 694 829 B1 and US 012.8224 A1
2- 2005: Publication: Frédéric TANGY and Hussein Y. Naim. Live Attenuated Measles Vaccine as a Potential Multivalent Pediatric Vaccination Vector.
VIRAL IMMUNOLOGY, Volume 18, Number 2, 2005, page 317-326
3- 2011: Inventor in Patent US 8,343,718 B2
4- 2014: Publication: Nicolas Escriou, ,Benoît Callendret, Valérie Lorin, Chantal Combredet, Philippe Marianneau, Michèle Février, Frédéric Tangy. Protection contre le coronavirus du SRAS conférée par le vaccin vivant contre la rougeole exprimant la glycoprotéine de pointe.
Virology, Volumes 452–453, March 2014, page 32-41
5- 2020: Paris-Match article from April 9-15, 2020
6- 2020: Paris-Match article from May 14-20, 2020
Doctor Frédéric Tangy is the father of the Covid-19
Frédéric Tangy
COVID-19 is an artificial coronavirus made in France by the Institut Pasteur from natural Sars-CoV coronavirus
Covid-19 is the result of several genetic manipulations of a strain of Coronavirus Sars-CoV, associated with severe acute respiratory syndrome (SARS), resulting from a sample listed under the number 031589, collected from bronchoalveolar washings of Sars infected patients by scientists of Institut Pasteur, before 2003, at the French hospital in Hanoi (Vietnam)
– 1st Step: Sars-CoV-1 was produced by a first patent (2003: European Patent EP1 69 48 29 B1 and US Patent US 012.8224 A1) from Sars-CoV collected in Hanoi before200 3 – 2nd Step: Sars-CoV-2 was a continuation of the first US patent US 012.8224 A1,p rotected by the second US Patent US 8,243,718 B2 (2011), from Sars-CoV-1 – 3rd Step: Covid-19 was produced from Sars-Cov-2 by inserting into its genome 4 sequences of HIV1 (RNA AIDS virus)
Finally
Covid-19 was made in France by French scientists at the Institut Pasteur from Sars-CoV, then transferred to Wuhan where the French scientists of Institut Pasteur do let it escape, unbeknownst to scientists in the Wuhan laboratory and the Chinese government
When she says: “Covid-19 is not a Chinese virus”, CHINA DOES NOT LIE!
| From Sars-CoV
to Sars-CoV1 |
From Sars-CoV to Sars-CoV1 2003
Institut Pasteur Frédéric Tangy
1 DNA sequence of 29746 nucleotides
+ 157 DNA and PRT sequences
inserted into RNA genome of Sars-CoV
Sars-CoV Sars-CoV1
Collected at French Hospital of Hanoi,
by Institut Pasteur (sample n° 031589) Patent EP 1 694 829 B1
Patent US 012.8224 A1
First Patent US 2007/0128224 A1
Patent US 2007/0128224 A1
Claims 1
Patent US 2007/0128224 A1
Claims 2
Insertion of a first DNA sequence (29746 nucleotides) in the genome of Sars-Cov collected in the French hospital at Hanoi (Vietnam)
Listing of the 158 DNA and Protein sequences inserted, by Pasteur Institute people, into the Sars-CoV coronavirus, taken, in 2003, from a patient at the French hospital in Hanoi
Sars-CoV1: SEQUENCE 1
DNA
Sars-CoV1: SEQUENCE 2
DNA
Listing of the 158 DNA and Protein sequences inserted, by Pasteur Institute people, into the Sars-CoV coronavirus, taken, in 2003, from a patient at the French hospital in Hanoi Following up
Sars-CoV1: SEQUENCE 3
PRT
Sars-CoV1: SEQUENCE 16
DNA
Sars-CoV1: SEQUENCE 28
PRT
Listing of the 158 DNA and Protein sequences inserted, by Pasteur Institute people, into the Sars-CoV coronavirus, taken, in 2003, from a patient at the French hospital in Hanoi Following up
Sars-CoV1: SEQUENCE 31
DNA
Sars-CoV1: SEQUENCE 46
DNA
Sars-CoV1: SEQUENCE 55
DNA
Listing of the 158 DNA and Protein sequences inserted, by Pasteur Institute people, into the Sars-CoV coronavirus, taken, in 2003, from a patient at the French hospital in Hanoi Following up
Sars-CoV1: SEQUENCE 61
DNA
Sars-CoV1: SEQUENCE 69
PRT
Sars-CoV1: SEQUENCE 73
DNA
Sars-CoV1: SEQUENCE 74
PRT
Listing of the 158 DNA and Protein sequences inserted, by Pasteur Institute people, into the Sars-CoV coronavirus, taken, in 2003, from a patient at the French hospital in Hanoi Following up
Sars-CoV1: SEQUENCE 88
DNA
Sars-CoV1: SEQUENCE 89
DNA
Sars-CoV1: SEQUENCE 90
DNA
Sars-CoV1: SEQUENCE 91
DNA
Listing of the 158 DNA and Protein sequences inserted, by Pasteur Institute people, into the Sars-CoV coronavirus, taken, in 2003, from a patient at the French hospital in Hanoi Following up
Sars-CoV1: SEQUENCE 121
DNA
Sars-CoV1: SEQUENCE 122
DNA
Sars-CoV1: SEQUENCE 123
DNA
Sars-CoV1: SEQUENCE 124
DNA
Listing of the 158 DNA and Protein sequences inserted, by Pasteur Institute people, into the Sars-CoV coronavirus, taken, in 2003, from a patient at the French hospital in Hanoi Following up
Sars-CoV1: SEQUENCE 140
DNA
Sars-CoV1: SEQUENCE 157
DNA
Sars-CoV1: SEQUENCE 158
DNA
| From Sars-CoV1
to Sars-CoV2 |
From Sars-CoV1 to Sars-CoV2 2011
Institut Pasteur
Frédéric Tangy
Sars-CoV1
Produced by inserting 1 DNA sequence (29746 nucleotides) + 157 DNA and PRT sequences into the Sars-CoV RNA genome
CONTINUATION OF
Patent EP 1 694 829 B1
Patent US 012.8224 A1
Patent US 8,243,718 B2
Sars-CoV2
Patent US 8,243,718 B2 continuation of First Patent US 2007/012.8224 A1
| From Sars-CoV2
to Covid-19 |
From Sars-CoV2 to Covid-19 2019
Institut Pasteur Frédéric Tangy
Insertion of 4 fragments of HIV1,
corresponding to short segments of a. a..
found in the gp 120 and the Gag of HIV1,
in the Sars-CoV2 genome
Sars-CoV2 Covid-19
Patent filed in 2019
International Publication date in 2021
Transformation of Sars-CoV-2 into Covid-19
The Sars-CoV-2 coronavirus, described in US Patent 8,343,718 B2 , is an RNA virus into the genome of which DNA sequences, but not RNA sequences, have been inserted.
Recently, and simultaneously, Professor Luc Montagnier and a group of Indian scientists have analyzed and decrypted the complete genome of the Covid-19 coronavirus responsible for the pandemic.
They found in the Covid-19 genome:
– sequences of HIV, the AIDS virus (4 fragments of HIV1 RNA which correspond to short segments of amino acids found in the gp120 and the Gag of HIV1);
– and DNA sequences from the malaria germ.
These results have been published and confirmed by Professor Peter Chumakov, a well-known Russian microbiologist, and Japanese Professor Tasuku Honjo, 2018 Nobel Prize laureate in medicine. Since there was no RNA sequence in Sars-CoV-2 described in US Patent 8,343,718 B2, this analysis proves that Covid-19 is the result of genetic manipulation of Sars-CoV-2 by French scientists from the Institut Pasteur.
Interview with professor Luc Montagnier by doctor Jean-François Lemoine Health site: Medical Frequency and Why Doctor
(Thursday April 16, 2020)
To read this interview, see DOCUMENT 1
To read the full article see DOCUMENT 2
VIRAL IMMUNOLOGY, Volume 18, Number 2,
2005 © Mary Ann Liebert, Inc.
Pages 317-326
Review
Live Attenuated Measles Vaccine
as a Potential Multivalent Pediatric Vaccination Vector
FRÉDÉRIC TANGY1and HUSSEIN Y. NAIM2
(1- Unité des Virus Lents, CNRS URA 1930, Institut Pasteur, Paris, France. 2- Berna Biotech LTD, Rehhagstrasse 79, 3018 Bern, Switzerland)
ABSTRACT
Live attenuated RNA viruses make highly efficient vaccines. Among them is the live attenuated measles virus (MV) vaccine that has been given to a very large number of children and has been shown to be highly efficacious and safe. MV vaccine induces a life-long immunity after a single injection or two low-dose injections. It is easily produced on a large scale in most countries and can be distributed at low cost. Reversion to pathogenicity bas never been observed with this vaccine. For all of these characteristics, developing of MV vaccine vector as a multivalent vaccine to immunize children against both measles and other infectious agents such as human immunodeficiency virus (HIV), flaviviruses, or malaria might be very promising for worldwide use. As MV vaccine is inexpensive to produce, the generation of recombinant vaccines may remain affordable and attractive for the developing world. In this article, we describe the development of MV vector and present some recent data showing the capacity of recombinant MV vaccine to express various proteins from HIV and West Nile virus. In addition, the ability of recombinant MV to induce specific immune responses against these different pathogens are presented and discussed.
Interview with Doctor Frédéric Tangy
Paris-Match article from April 9-15, 2020
To read this interview
See DOCUMENT 3 (Original) and DOCUMENT 4 (English traduction)
Elaboration of Covid-19 vaccine according to Dr Frédéric Tangy
The complete and detailed «recipe» for one Covid 19 vaccine, was given to us by Dr Frédéric Tangy, head of Vaccine Innovation at the Institut Pasteur in Paris, in an interview with the newspaper Paris-Match, in the 9-15 edition April 2020 (See Documents 3 and 4)
Thus, as explained perfectly to us by Dr. Frédéric Tangy – who is decidedly very talkative – the spike glycoprotein of Covid-19, which contains the 4 RNA sequences of HIV– which is clear from the group’s analysis of Indian researchers, but was hidden (like DNA sequences of malaria genome) by scientists at the Institut Pasteur – is intended, he said, to induce immunity in the vaccine, serving as an antigen after insertion into the genome of the attenuated measles virus (who remember it is an RNA virus). But, obviously, it does not tell us that the RNA HIV nucleic acids, which have already been previously inserted into the genome of Sars-CoV2 coronavirus, are those of HIV. And, since it is not in the Sars-CoV-2 coronavirus genome, one wonders where it came from !
It should be noted that Dr. Frédéric Tangy gave this interview a few days before that of Pr Luc Montagnier
| From Covid-19
to Covid-19 Vaccines |
From Covid-19 to Covid-19 Vaccines Covid-19
Insertion of Covid-19 genome into the genome of a viral vector
(ChAdOx1 chimpanzee DNA adenovirus)
Jenner
Institute
Adrian Hill
Covid-19 vaccines
ChAdOx1 nCoV-19 (AstraZeneca, Sanofi) Insertion of tracing nanoparticles
in the vaccine vial to be injected into the human body
together with the vaccine
US Patent WO 2020/060606 A1 PCT/US20 19/038084 Microsoft
Final vaccine
Bill Gates
NANOPARTICLES OF Covid-19 VACCINES
Vaccinated people
Satellites for 5G
Task server
Nanoparticles 5G relays
injected
together with vaccine
Nanoparticles
Mobile phones
Bill Gates
Nanoparticles and the permanent control of vaccinated people
The nanoparticles described in the Microsoft patent (US Patent WO 2020/060606 A1) are sensors which must be diffused in the body of the vaccinated person, in order to be able to detect it
Introduced into the vaccine vial, they are injected into the body, together with the vaccine, at the time of vaccination
Once they are in the body, they cannot be gotten rid of, unlike a subcutaneous digital tracing microchip. From this moment, the vaccinated people will be detectable by any mobile phone located nearby.
Mobile phones are connected to the internet by 5G
5G relays allow this communication through satellites 5G.
The vaccinated people will have lost definitely all freedom in their existence
Are 160 Covid-19 vaccines really in development?
According to information provided by the NIH and WHO, 160 vaccines against Covid-19 are under development
The list of the 160 candidates for Covid-19 vaccines in development was compiled by the NIH
Of these160 candidates
only 21 clinical study protocols
have been written by the NIH
List of candidates for Covid-19 vaccines in development DRAFT landscape of COVID-19 candidate vaccines – 7 July 2020 21 candidate vaccines in clinical evaluation
| Platform | Type of
candidate vaccine |
Developer | Coronavirus target | Current stage of clinical
evaluation/regulatory status Coronavirus candidate |
Same platform for non-Coronavirus candidates |
| Inactivated | Inactivated +
alum |
Sinovac | SARS-CoV2 | Phase 3
NCT04456595 Phase 1/2 NCT04383574 NCT04352608 |
SARS |
| Non
Replicating Viral Vector |
ChAdOx1-S | University of
Oxford/AstraZeneca |
SARS-CoV2 | Phase 3
ISRCTN89951424 Phase2b/3 2020-001228-32 Phase 1/2 PACTR202006922165132 2020-001072-15 |
MERS, influenza, TB, Chikungunya, Zika, MenB, plague |
| Non
Replicating Viral Vector |
Adenovirus Type 5 Vector | CanSino Biological
Inc./Beijing Institute of Biotechnology |
SARS-CoV2 | Phase 2
ChiCTR2000031781 Phase 1 ChiCTR2000030906 |
Ebola |
| RNA | LNP
encapsulated mRNA |
Moderna/NIAID | SARS-CoV2 | Phase 2
NCT04405076 Phase 1 NCT04283461 |
multiple candidates |
| DNA | DNA plasmid
vaccine with electroporation |
Inovio Pharmaceuticals/ International Vaccine
Institute |
SARS-CoV2 | Phase 1/2
NCT04447781 NCT04336410 |
multiple candidates |
| DNA | DNA plasmid
vaccine |
Cadila Healthcare Limited | SARS-CoV2 | Phase 1/2
CTRI/2020/07/026352 (not yet recruiting) |
|
| Inactivated | Inactivated | Wuhan Institute of
Biological Products/Sinopharm |
SARS-CoV2 | Phase 1/2
ChiCTR2000031809 |
|
| Inactivated | Inactivated | Beijing Institute of
Biological Products/Sinopharm |
SARS-CoV2 | Phase 1/2
ChiCTR2000032459 |
|
| Protein
Subunit |
Full length
recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M |
Novavax | SARS-CoV2 | Phase 1/2
NCT04368988 |
RSV; CCHF, HPV, VZV, EBOV |
| RNA | 3 LNP-mRNAs | BioNTech/Fosun
Pharma/Pfizer |
SARS-CoV2 | Phase 1/2
2020-001038-36 NCT04368728 |
|
| DNA | DNA Vaccine
(GX-19) |
Genexine Consortium | SARS-CoV2 | Phase 1
NCT04445389 |
|
| DNA | DNA plasmid
vaccine + Adjuvant |
Osaka University/ AnGes/ Takara Bio | SARS-CoV2 | Phase 1
JapicCTI-205328 |
DISCLAIMER:
These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.
FOLLOWING
| Inactivated | Inactivated | Institute of Medical Biology , Chinese Academy of
Medical Sciences |
SARS-CoV2 | Phase 1
NCT04412538 |
|
| Non
Replicating Viral Vector |
Adeno-based | Gamaleya Research
Institute |
SARS-CoV2 | Phase 1
NCT04436471 NCT04437875 |
|
| Protein
Subunit |
Native like
Trimeric subunit Spike Protein vaccine |
Clover Biopharmaceuticals Inc./GSK/Dynavax | SARS-CoV2 | Phase 1
NCT04405908 |
HIV, REV Influenza |
| Protein
Subunit |
Adjuvanted
recombinant protein (RBD Dimer) |
Anhui Zhifei Longcom
Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences |
SARS-CoV2 | Phase 1
NCT04445194 |
MERS |
| Protein
Subunit |
Recombinant
spike protein with Advax™ adjuvant |
Vaxine Pty Ltd/Medytox | SARS-CoV2 | Phase 1
NCT04453852 |
|
| RNA | LNP-nCoVsaRNA | Imperial College London | SARS-CoV2 | Phase 1
ISRCTN17072692 |
EBOV; LASV, MARV, Inf (H7N9), RABV |
| RNA | mRNA | Curevac | SARS-CoV2 | Phase 1
NCT04449276 |
RABV, LASV, YFV; MERS, InfA, ZIKV, DENV, NIPV |
| RNA | mRNA | People’s Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech. | SARS-CoV2 | Phase 1
ChiCTR2000034112 |
|
| VLP | Plant-derived
VLP |
Medicago Inc./ Université Laval | SARS-CoV2 | Phase 1
NCT04450004 (not yet recruiting) |
Flu, Rotavirus,
Norovirus, West Nile virus, Cancer |
FOLLOWING
139 candidate vaccines in preclinical evaluation
| Platform | Type of candidate vaccine | Developer | Coronavirus target | Current stage of clinical evaluation/regulatory status- Coronavirus candidate | Same platform for non
Coronavirus candidates |
| DNA | DNA vaccine | Ege University | SARS-CoV2 | Pre-Clinical | |
| DNA | DNA plasmid vaccine RBD&N | Scancell/University of Nottingham/ Nottingham Trent University | SARS-CoV2 | Pre-Clinical | |
| DNA | DNA plasmid vaccine S,S1,S2,RBD &N | National Research Centre, Egypt | SARS-CoV2 | Pre-Clinical | |
| DNA | DNA with
electroporation |
Karolinska Institute / Cobra
Biologics (OPENCORONA Project) |
SARS-CoV2 | Pre-Clinical | |
| DNA | DNA with
electroporation |
Chula Vaccine Research Center | SARS-CoV2 | Pre-Clinical | |
| DNA | DNA | Takis/Applied DNA
Sciences/Evvivax |
SARS-CoV2 | Pre-Clinical | |
| DNA | Plasmid DNA, Needle Free Delivery | Immunomic Therapeutics,
Inc./EpiVax, Inc./PharmaJet |
SARS-CoV2 | Pre-Clinical | SARS |
| DNA | DNA vaccine | BioNet Asia | SARS-CoV2 | Pre-Clinical | |
| DNA | msDNA vaccine | Mediphage Bioceuticals/University of Waterloo | SARS-CoV2 | Pre-Clinical | |
| DNA | DNA vaccine | Entos Pharmaceuticals | SARS-CoV2 | Pre-Clinical | |
| DNA | bacTRL-Spike | Symvivo | SARS-CoV2 | Pre-Clinical | |
| Inactivated | Inactivated + alum | KM Biologics | SARS-CoV2 | Pre-Clinical | JE, Zika |
| Inactivated | Inactivated | Selcuk University | SARS-CoV2 | Pre-Clinical | |
| Inactivated | Inactivated whole
virus |
National Research Centre, Egypt | SARS-CoV2 | Pre-Clinical | |
| Inactivated | Inactivated | Beijing Minhai Biotechnology Co., Ltd. | SARS-CoV2 | Pre-Clinical |
DISCLAIMER:
These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.
FOLLOWING
| Inactivated | TBD | Osaka University/ BIKEN/ NIBIOHN | SARS-CoV2 | Pre-Clinical | |
| Inactivated | Inactivated + CpG
1018 |
Sinovac/Dynavax | SARS-CoV2 | Pre-Clinical | |
| Inactivated | Inactivated + CpG
1018 |
Valneva/Dynavax | SARS-CoV2 | Pre-Clinical | |
| Inactivated | Inactivated | Research Institute for Biological Safety Problems, Rep of Kazakhstan | SARS-CoV2 | Pre-Clinical | |
| Live
Attenuated Virus |
Codon deoptimized live attenuated
vaccines |
Mehmet Ali Aydinlar University / Acıbadem Labmed Health Services A.S. | SARS-CoV2 | Pre-Clinical | |
| Live
Attenuated Virus |
Codon deoptimized live attenuated
vaccines |
Codagenix/Serum Institute of India | SARS-CoV2 | Pre-Clinical | HAV, InfA, ZIKV, FMD, SIV, RSV, DENV |
| Live
Attenuated Virus |
Codon deoptimized live attenuated
vaccines |
Indian Immunologicals Ltd/Griffith University | SARS-CoV2 | Pre-Clinical | |
| Non
Replicating Viral Vector |
Sendai virus vector | ID Pharma | SARS-CoV2 | Pre-Clinical | |
| Non
Replicating Viral Vector |
Adenovirus-based | Ankara University | SARS-CoV2 | Pre-Clinical | |
| Non
Replicating Viral Vector |
Adeno-associated virus vector
(AAVCOVID) |
Massachusetts Eye and
Ear/Massachusetts General Hospital/AveXis |
SARS-CoV2 | Pre-Clinical | |
| Non
Replicating Viral Vector |
MVA encoded VLP | GeoVax/BravoVax | SARS-CoV2 | Pre-Clinical | LASV, EBOV,
MARV, HIV |
| Non
Replicating Viral Vector |
Ad26 | Janssen Pharmaceutical Companies | SARS-CoV2 | Pre-Clinical | Ebola, HIV, RSV |
| Non
Replicating Viral Vector |
Replication defective Simian Adenovirus (GRAd) encoding
SARS-CoV-2 S |
ReiThera/LEUKOCARE/Univercells | SARS-CoV2 | Pre-Clinical | |
| Non
replicating viral vector |
MVA-S encoded | DZIF – German Center for Infection Research/IDT Biologika GmbH | SARS-CoV2 | Pre-clinical | Many |
| Non
replicating viral vector |
MVA-S | IDIBAPS-Hospital Clinic, Spain | SARS-CoV2 | Pre-clinical | |
| Non
Replicating Viral Vector |
adenovirus-based NasoVAX expressing SARS2-CoV spike
protein |
Altimmune | SARS-CoV2 | Pre-Clinical | influenza |
| Non
Replicating Viral Vector |
[E1-, E2b-, E3-] hAd5- COVID19-
Spike/Nucleocapsid |
ImmunityBio, Inc. & NantKwest, Inc. | SARS-CoV2 | Pre-Clinical | flu, Chik, Zika, EBOV, LASV,
HIV/SIV,Cancer |
| Non
Replicating Viral Vector |
Ad5 S (GREVAX™
platform) |
Greffex | SARS-CoV2 | Pre-Clinical | MERS |
| Non
Replicating Viral Vector |
Oral Ad5 S | Stabilitech Biopharma Ltd | SARS-CoV2 | Pre-Clinical | Zika, VZV, HSV-2 and Norovirus |
| Non
Replicating Viral Vector |
adenovirus-based + HLA-matched
peptides |
Valo Therapeutics Ltd | Pan-Corona | Pre-Clinical | |
| Non
Replicating Viral Vector |
Oral Vaccine platform | Vaxart | SARS-CoV2 | Pre-Clinical | InfA, CHIKV,
LASV, NORV; EBOV, RVF, HBV, VEE |
| Non
Replicating Viral Vector |
MVA expressing
structural proteins |
Centro Nacional Biotecnología (CNB-CSIC), Spain | SARS-CoV2 | Pre-Clinical | Multiple
candidates |
| Non
Replicating Viral Vector |
Dendritic cell-based vaccine | University of Manitoba | SARS-CoV2 | Pre-Clinical |
DISCLAIMER:
These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.
FOLLOWING
| Non
Replicating Viral Vector |
parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein | University of Georgia/University of Iowa | SARS-CoV2 | Pre-Clinical | MERS |
| Non
Replicating Viral Vector |
Recombinant
deactivated rabies virus containing S1 |
Bharat Biotech/Thomas Jefferson University | SARS-CoV2 | Pre-Clinical | HeV, NiV, EBOV, LASSA, CCHFV, MERS |
| Non
Replicating Viral Vector |
Influenza A H1N1
vector |
National Research Centre, Egypt | SARS-CoV2 | Pre-Clinical | |
| Non
Replicating Viral Vector |
Inactivated Flu-based SARS-CoV2 vaccine + Adjuvant | National Center for Genetic
Engineering and Biotechnology (BIOTEC) /GPO, Thailand |
SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
Recombinant S
protein |
Izmir Biomedicine and Genome Center | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
Peptide + novel
adjuvant |
Bogazici University | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
S subunit intranasal liposomal formulation with GLA/3M052 adjs. | University of Virginia | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
Subunit | Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria. | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
Protein Subunit
S,N,M&S1 protein |
National Research Centre, Egypt | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
Protein Subunit | University of San Martin and CONICET, Argentina | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
RBD protein fused with Fc of IgG + Adj. | Chulalongkorn University/GPO, Thailand | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
Capsid-like Particle | AdaptVac (PREVENT-nCoV
consortium) |
SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
Drosophila S2 insect cell expression system VLPs | ExpreS2ion | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
Peptide antigens
formulated in LNP |
IMV Inc | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
S protein | WRAIR/USAMRIID | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
S protein +Adjuvant | National Institute of Infectious Disease, Japan/Shionogi/UMN Pharma | SARS-CoV2 | Pre-Clinical | Influenza |
| Protein
Subunit |
VLP-recombinant
protein + Adjuvant |
Osaka University/ BIKEN/ National Institutes of Biomedical Innovation, Japan | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
microneedle arrays S1 subunit | Univ. of Pittsburgh | SARS-CoV2 | Pre-Clinical | MERS |
| Protein
Subunit |
Peptide | Vaxil Bio | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
Adjuvanted protein subunit (RBD) | Biological E Ltd | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
Peptide | Flow Pharma Inc | SARS-CoV2 | Pre-Clinical | Ebola, Marburg, HIV, Zika,
Influenza, HPV therapeutic vaccine, BreastCA vaccine |
| Protein
Subunit |
S protein | AJ Vaccines | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
Ii-Key peptide | Generex/EpiVax | SARS-CoV2 | Pre-Clinical | Influenza, HIV, SARS-CoV |
| Protein
Subunit |
S protein | EpiVax/Univ. of Georgia | SARS-CoV2 | Pre-Clinical | H7N9 |
| Protein
Subunit |
Protein Subunit EPV CoV-19 | EpiVax | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
S protein (baculovirus production) | Sanofi Pasteur/GSK | SARS-CoV2 | Pre-Clinical | Influenza, SARS CoV |
DISCLAIMER:
These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.
FOLLOWING
| Protein
Subunit |
gp-96 backbone | Heat Biologics/Univ. Of Miami | SARS-CoV2 | Pre-Clinical | NSCLC, HIV,
malaria, Zika |
| Protein
Subunit |
Molecular clamp
stabilized Spike protein |
University of
Queensland/GSK/Dynavax |
SARS-CoV2 | Pre-Clinical | Nipah, influenza, Ebola, Lassa |
| Protein
Subunit |
Peptide vaccine | FBRI SRC VB VECTOR,
Rospotrebnadzor, Koltsovo |
SARS-CoV2 | Pre-Clinical | Ebola |
| Protein
Subunit |
Subunit vaccine | FBRI SRC VB VECTOR,
Rospotrebnadzor, Koltsovo |
SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
S1 or RBD protein | Baylor College of Medicine | SARS-CoV2 | Pre-Clinical | SARS |
| Protein
Subunit |
Subunit protein, plant produced | iBio/CC-Pharming | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
Recombinant protein, nanoparticles (based on S-protein and
other epitopes) |
Saint-Petersburg scientific research institute of vaccines and serums | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
COVID-19 XWG-03 truncated S (spike) proteins | Innovax/Xiamen Univ./GSK | SARS-CoV2 | Pre-Clinical | HPV |
| Protein
Subunit |
Adjuvanted
microsphere peptide |
VIDO-InterVac, University of Saskatchewan | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
Synthetic Long
Peptide Vaccine candidate for S and M proteins |
OncoGen | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
Oral E. coli-based protein expression system of S and N proteins | MIGAL Galilee Research Institute | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
Nanoparticle vaccine | LakePharma, Inc. | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
Plant-based subunit (RBD-Fc + Adjuvant) | Baiya Phytopharm/ Chula Vaccine Research Center | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
OMV-based vaccine | Quadram Institute Biosciences | SARS-CoV2 | Pre-Clinical | Flu A, plague |
| Protein
Subunit |
OMV-based vaccine | BiOMViS Srl/Univ. of Trento | SARS-CoV2 | Pre-Clinical | |
| Protein
subunit |
structurally modified spherical particles of the tobacco mosaic virus (TMV) | Lomonosov Moscow State
University |
SARS-CoV2 | Pre-Clinical | rubella,
rotavirus |
| Protein
Subunit |
Spike-based | University of Alberta | SARS-CoV2 | Pre-Clinical | Hepatitis C |
| Protein
Subunit |
Recombinant S1-Fc fusion protein | AnyGo Technology | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
Recombinant protein | Yisheng Biopharma | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
Recombinant S
protein in IC-BEVS |
Vabiotech | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
Orally delivered, heat stable subunit | Applied Biotechnology Institute, Inc. | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
S-2P protein + CpG 1018 | Medigen Vaccine Biologics
Corporation/NIAID/Dynavax |
SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
Peptides derived from Spike protein | Axon Neuroscience SE | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
Protein Subunit | MOGAM Institute for Biomedical Research, GC Pharma | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
RBD-based | Neovii/Tel Aviv University | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
RBD-based | Kentucky Bioprocessing, Inc | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
Outer Membrane
Vesicle (OMV)- subunit |
Intravacc/Epivax | SARS-CoV2 | Pre-Clinical | |
| Protein
Subunit |
Outer Membrane
Vesicle(OMV)-peptide |
Intravacc/Epivax | SARS-CoV2 | Pre-Clinical |
DISCLAIMER:
These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.
FOLLOWING
| Protein
Subunit |
Spike-based (epitope screening) | ImmunoPrecise/LiteVax BV | SARS-CoV2 | Pre-Clinical | |
| Replicating Viral Vector | YF17D Vector | KU Leuven | SARS-CoV2 | Pre-Clinical | |
| Replicating Viral Vector | Measles Vector | Cadila Healthcare Limited | SARS-CoV2 | Pre-Clinical | |
| Replicating Viral Vector | Measles Vector | Institute Pasteur/Themis/Univ. of Pittsburg Center for Vaccine Research/Merck | SARS-CoV2 | Pre-Clinical | West nile, chik, Ebola, Lassa,
Zika |
| Replicating Viral Vector | Measles Vector | FBRI SRC VB VECTOR,
Rospotrebnadzor, Koltsovo |
SARS-CoV2 | Pre-Clinical | |
| Replicating Viral Vector | Measles Virus (S, N targets) | DZIF – German Center for Infection Research/CanVirex AG | SARS-CoV2 | Pre-clinical | Zika, H7N9,
CHIKV |
| Replicating Viral Vector | Horsepox vector
expressing S protein |
Tonix Pharma/Southern Research | SARS-CoV2 | Pre-Clinical | Smallpox,
monkeypox |
| Replicating Viral Vector | Live viral vectored vaccine based on
attenuated influenza virus backbone (intranasal) |
BiOCAD and IEM | SARS-CoV2 | Pre-Clinical | Influenza |
| Replicating Viral Vector | Recombinant vaccine based on Influenza A virus, for the
prevention of COVID 19 (intranasal) |
FBRI SRC VB VECTOR,
Rospotrebnadzor, Koltsovo |
SARS-CoV2 | Pre-Clinical | Influenza |
| Replicating Viral Vector | Attenuated Influenza expressing
an antigenic portion of the Spike protein |
Fundação Oswaldo Cruz and
Instituto Buntantan |
SARS-CoV2 | Pre-Clinical | Influenza |
| Replicating Viral Vector | Influenza vector
expressing RBD |
University of Hong Kong | SARS-CoV2 | Pre-Clinical | |
| Replicating Viral Vector | Replication
competent VSV chimeric virus technology (VSVΔG) delivering the SARS CoV-2 Spike (S) glycoprotein. |
IAVI/Merck | SARS-CoV2 | Pre-Clinical | Ebola, Marburg, Lassa |
| Replicating Viral Vector | VSV-S | University of Western Ontario | SARS-CoV2 | Pre-Clinical | HIV, MERS |
| Replicating Viral Vector | VSV vector | FBRI SRC VB VECTOR,
Rospotrebnadzor, Koltsovo |
SARS-CoV2 | Pre-Clinical | |
| Replicating Viral Vector | VSV-S | Israel Institute for Biological Research/Weizmann Institute of Science | SARS-CoV2 | Pre-Clinical | |
| Replicating Viral Vector | M2-deficient single replication (M2SR) influenza vector | UW–Madison/FluGen/Bharat Biotech | SARS-CoV2 | Pre-Clinical | influenza |
| Replicating Viral Vector | Newcastle disease virus vector (NDV
SARS-CoV-2/Spike) |
Intravacc/ Wageningen
Bioveterinary Research/Utrecht Univ. |
SARS-CoV2 | Pre-Clinical | |
| Replicating Viral Vector | Avian paramyxovirus vector (APMV) | The Lancaster University, UK | SARS-CoV2 | Pre-Clinical | |
| RNA | mRNA | Selcuk University | SARS-CoV2 | Pre-Clinical | |
| RNA | LNP-mRNA | Translate Bio/Sanofi Pasteur | SARS-CoV2 | Pre-Clinical | |
| RNA | LNP-mRNA | CanSino Biologics/Precision
NanoSystems |
SARS-CoV2 | Pre-Clinical | |
| RNA | LNP-encapsulated mRNA cocktail
encoding VLP |
Fudan University/ Shanghai
JiaoTong University/RNACure Biopharma |
SARS-CoV2 | Pre-Clinical | |
| RNA | LNP-encapsulated mRNA encoding RBD | Fudan University/ Shanghai
JiaoTong University/RNACure Biopharma |
SARS-CoV2 | Pre-Clinical | |
| RNA | Replicating Defective SARS-CoV-2 derived RNAs | Centro Nacional Biotecnología (CNB-CSIC), Spain | SARS-CoV2 | Pre-Clinical | |
| RNA | LNP-encapsulated mRNA | University of Tokyo/ Daiichi-Sankyo | SARS-CoV2 | Pre-Clinical | MERS |
DISCLAIMER:
These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.
FOLLOWING
| RNA | Liposome
encapsulated mRNA |
BIOCAD | SARS-CoV2 | Pre-Clinical | |
| RNA | Several mRNA
candidates |
RNAimmune, Inc. | SARS-CoV2 | Pre-Clinical | |
| RNA | mRNA | FBRI SRC VB VECTOR,
Rospotrebnadzor, Koltsovo |
SARS-CoV2 | Pre-Clinical | |
| RNA | mRNA | China CDC/Tongji
University/Stermina |
SARS-CoV2 | Pre-Clinical | |
| RNA | mRNA | Arcturus/Duke-NUS | SARS-CoV2 | Pre-Clinical | multiple
candidates |
| RNA | LNP-mRNA | Chula Vaccine Research
Center/University of Pennsylvania |
SARS-CoV2 | Pre-Clinical | |
| RNA | mRNA in an intranasal delivery system | eTheRNA | SARS-CoV2 | Pre-Clinical | |
| RNA | mRNA | Greenlight Biosciences | SARS-CoV2 | Pre-Clinical | |
| RNA | mRNA | IDIBAPS-Hospital Clinic, Spain | SARS-CoV2 | Pre-Clinical | |
| VLP | VLP | Middle East Technical University | SARS-CoV2 | Pre-Clinical | |
| VLP | Enveloped Virus-Like Particle (eVLP) | VBI Vaccines Inc. | SARS-CoV-2, SARS-CoV, & MERS-CoV | Pre-Clinical | CMV, GBM, Zika |
| VLP | S protein integrated in HIV VLPs | IrsiCaixa AIDS Research/IRTA CReSA/Barcelona Supercomputing Centre/Grifols | SARS-CoV2 | Pre-Clinical | |
| VLP | VLP + Adjuvant | Mahidol University/ The
Government Pharmaceutical Organization (GPO)/Siriraj Hospital |
SARS-CoV2 | Pre-Clinical | |
| VLP | Virus-like particles, lentivirus and
baculovirus vehicles |
Navarrabiomed, Oncoimmunology group | SARS-CoV2 | Pre-Clinical | |
| VLP | Virus-like particle, based on RBD
displayed on virus-like particles |
Saiba GmbH | SARS-CoV2 | Pre-Clinical | |
| VLP | ADDomerTM
multiepitope display |
Imophoron Ltd and Bristol
University’s Max Planck Centre |
SARS-CoV2 | Pre-Clinical | |
| VLP | Unknown | Doherty Institute | SARS-CoV2 | Pre-Clinical | |
| VLP | VLP | OSIVAX | SARS-CoV1 SARS-CoV2 | Pre-Clinical | |
| VLP | eVLP | ARTES Biotechnology | SARS-CoV2 | Pre-Clinical | malaria |
| VLP | VLPs peptides/whole virus | Univ. of Sao Paulo | SARS-CoV2 | Pre-Clinical | |
| Unknown | Unknown | Tulane University | SARS-CoV2 | Pre-Clinical |
DISCLAIMER:
These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.
The time required to develop a new vaccine since the discovery of a new virus until the Marketing Authorization At least 13 years
– Identification of the virus responsible for the epidemic: 1 year
– Development of a vaccine: 8 years, according to Dr Frédéric Tangy in Paris-Match from 14-20 May 2020 – Preclinical studies : analytical, galenical, and toxicological in animals: 1 year – Study in humans:
– Phase I: in healthy volunteers after favorable opinion of Protection Committee, and Free an Informed Consent of healthy voluntary subjects : 6 months to 1 year
– Phase II: in 100 to 1000 subjects after favorable opinion of Protection Committee and Free and Informed Consent of all subjects: 6 months to 1 year
– Phase III: in 10 000 to 100 000 subjects or more after favorable opinion of Protection Committee and Free and Informed Consent of all subjects: 6 months to 1 year
During development you cannot go from one study phase to the next, without having the results of the previous phase
Protocols for clinical studies of 2 Covid-19 vaccines ChAdOx1 nCoV-19 and mRNA-1273 vaccines
(Written by the N.I.H.)
1- Protocol of the University of Oxford / Astra Zeneca Phase I study with the ChAdOx1 nCoV-19 vaccine
– Sponsor of the study: Research Services, University Offices Wellington Square, Oxford, 1200, United Kingdom
– Country of the study: South Africa
– Summary of the study: A Phase I/II, double-blinded, placebo-controlled, individually randomized trial to assess safety, immunogenicity and efficacy of the candidate Coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults aged 18-65 years living with and without HIV in South Africa. The vaccine or placebo will be administered via an intramuscular injection into the deltoid muscle of the non dominant arm. A total of 2000 participants will be enrolled into the trial; 1950 HIV-uninfected and 50 people living with HIV. There will be 4 trial groups, group 1 (n=50; intensive safety & immunogenicity cohort, HIV negative), group 2a (n=250; safety, intense immunogenicity & efficacy), group 2b (n=1650; safety, immunogenicity & vaccine efficacy) and group 3 (n=50, intensive safety & immunogenicity cohort, HIV positive). Participants will be followed up for 12 months after enrollment.
– Ethics Approval: approval given on May, 21, 2020, by University of the Witwatersrand Human Research Ethics Committee Medical, 31 Princess of Wales Terrace, Parktown, Johannesburg, 2193, South Africa
– 2000 healthy volunteer subjects aged between 18 and 65 years
– Starting of the study: June 24, 2020
– End of the study: December 31, 2021
Protocols for clinical studies of 2 Covid-19 vaccines
ChAdOx1 nCoV-19 and mRNA-1273 vaccines
(Written b y th e N .I.H.)
Following
2 – Protocol of the University of Oxford / Astra Zeneca Phase II / III study with the ChAdOx1 nCoV-19 vaccine
– Title of the study: A phase 2/3 study to determine the efficacy, safety and immunogenicity of t he candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 n CoV-19
– Country of the study: United-Kingdom
– Sponsor of the study: ResearchServices, U niversity Offices Wellington Squa re, Oxford,1200, U nited Kingdom
– Summary of the study: To e valuate the e fficacy o f the candidate ChAdOx1 nCoV-19 in adults aged 18 and over.To a ssess t he safety of t he C hAdOx1 n CoV-19 vaccine candidate in adults a nd c hildren.To a ssess the safety, tolerability and reactogenicity profile of the ChAdOx1 nCoV-19 candidate
– Favorable opinion of the Competent Authority: April 5 , 2020
– Favorable opinion of the Ethics Committee: April 8 , 2020
– 12 390 healthy volunteer subjects divided into 4 age g roups: 60 under the age of 18. 60 children aged between 2 and 11 years old. 12,030 adults aged be tween 18 and 64 years o ld. 240 subjects aged over 65
– Starting of the st udy: May, 2020
– End of the study: May, 2021
Protocols for clinical studies of 2 Covid-19 vaccines ChAdOx1 nCoV-19 and mRNA-1273 vaccines
(Written by the N.I.H.)
Following
3- University of Oxford / Astra Zeneca Phase III study protocol with ChAdOx1 nCoV-19 vaccine
– Title of the study: A phase III randomized controlled trial to determine safety, efficacy, and immunogenicity of the non-replicating ChAdOx1 nCoV-19 vaccine
– Country of the study: Brazil
– Ethics approval: Approval pending:
- The National Commission for Research Ethics (Comissão Nacional de Ética em Pesquisa, (CONEP) – Brazil 2. Oxford Tropical Research Ethics Committee (OxTREC) – UK
– 2000 healthy volunteer subjects aged between 18 and 55 years
– Starting of the study: May 1, 2020
– End of the study: July 31, 2021
Protocols for clinical studies of 2 Covid-19 vaccines
ChAdOx1 nCoV-19 and mRNA-1273 vaccines
(Written by the N.I.H.)
Following
4- Protocol for Phase I study of Moderna with their new vaccine mARN-1273
– Title of the study: Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV2 Infection COVID-19. This is a phase I, open-label, dose-ranging clinical trial in males and nemales, starting at 18 years of age
– Sponsor of the study: National Institute of Allergy and Infectious Diseases (NIAID)
– Country of the study: United States of America (Georgia, Maryland, Washington)
– Summary of the study: This is a phase I, open-label, dose-ranging clinical trial in males and non-pregnant females, starting 18 years of age, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of mRNA-1273 manufactured by ModernaTX, Inc. mRNA-1273 is a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized spike (S) protein of SARS-CoV-2. Enrollment will occur at up to 3 domestic clinical research sites. One hundred and fifty-five subjects will be enrolled into one of thirteen cohorts (10 micrograms [mcg], 25 mcg, 50 mcg, 100 mcg, and 250 mcg). Subjects will receive an intramuscular (IM) injection (0.5 milliliters [mL]) of mRNA-1273 on Days 1 and 29 in the deltoid muscle and will be followed through 12 months post second vaccination (Day 394). Follow-up visits will occur 1, 2, and 4 weeks post each vaccination (Days 8, 15, 29, 36, 43, and 57), as well as 3, 6, and 12 months post second vaccination (Days 119, 209, and 394).
– Ethics approval: ???
– 155 healthy volunteer subjectsaged between 18 and 99 years
– Starting of the study: March 16, 2020
– End of the study: November 22, 2021
Protocols for clinical studies of 2 Covid-19 vaccines ChAdOx1 nCoV-19 and mRNA-1273 vaccines
(Written by the N.I.H.)
Following
5- Protocol for Phase II study of Moderna with their new vaccine mARN-1273
– Title of the study: A Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine in Adults Aged 18 Years and Older
– Sponsor of the study: Moderna TX, Inc.
– Collaborators: Biomedical Advanced Research and Development Authority
– Country of the study: United States of America .
– Locations: Georgia, Kansas, Missouri, Nebraska, North Carolina, South Dakota, Texas, Utah. – Ethics approval: Studies a U.S. FDA-regulated Drug Product ???
– 600 healthy volunteer subjects aged between 18 and 55+
– Starting of the study: May 20, 2020
– End of the study: August, 2021
COVID-19 Vaccine: ChAdOx1 nCoV-19
According to information provided by the NIH and WHO, 160 vaccines against Covid-19 are under development. But, after reviewing Phase 1, 2 and 3 clinical studies, the protocols of which were all written by the NIH, and their advancement, we came to the following c onclusion:
The only vaccine that has been developed
and already manufactured for several months
is the ChAdOx1 nCoV-19
All other 159 vaccines are “decoys”
ChAdOx1 nCoV-19 is the r esult of a co llaboration between the Institut Pasteur (Sanofi) and th e Jenner Institute (AstraZeneca).
In ChAdOx1 nCoV-19 , the genome of Covid-19 coronavirus is carried by the Chimpanzee adenovirus ChAdOx1, which serve s as a viral vector
COVID-19 Vaccine: ChAdOx1 n-CoV-19
In the only v accine de veloped and put into production, t he genome of the Covid-19 coronavirus is carried by the Chimpanzee adenovirus ChAdOx1, which serves as a viral vector
ChAdOx1 nCoV-19: C ovid-19 coronavirus carried
by the vector virus ChAdOx1 Nanoparticles described in Micr osoftPaten t PCT/ U S201 9/ 038084 ,which will control you t hanks t o 5 G
Disinfectant : s: either T himerosal
or Formaldehyde
and antibiotics
To read the full article see DOCUMENT 5 (Download PDF)
To read the original interview see Document 6
Extract from the interview with Dr Tangy in PARIS-MATCH from May 14-20, 2020
Among the 400 emails received each day by Professor Etienne Simon-Lorière, responsible for the functional genomic unit for infectious diseases, there is always one sent by an unknown person who found his contact on the Internet: where are they? vaccine research? On this point, Frédéric Tangy, head of the vaccine innovation laboratory, does not want to leave any doubt. With a sigh, he said: “There will be no miracle vaccine in November or December. At best, it will be in 2021.” He even plagues against figures which, according to him, sow confusion. Thus, those of the London School of Hygiene & Tropical Medicine which has just listed 120 vaccines in development in the world…. “It can be misleading. There are maybe only eight that will result! And of those, tested in China, Britain, Germany or the United States, few are expected to progress from phase 1 to phase 2 of human clinical trials. Industrialists know this very well: most are just new strategies, having not yet shown any clinical proof. I call them “mouse vaccines”. Vaccine science, the real one, the one that works, doesn’t move that way. In half an hour, he will transmit a videoconference, recorded the day before, to an audience of scientists from the Academy of Sciences. It deals specifically with the steps required to develop a vaccine. “Look at my diagrams: a vaccine is at least eight years of research! The AIDS vaccine has been on it for thirty-five years, and it’s still very difficult.
According to Dr Frédéric Tangy, the father of Covid-19, it takes at least 8 years to develop a vaccine (interview in Paris-Match from May 16 to 20, 2020)
Interview with Bill Gates Paris-Match April 16-22, 2020
Bill Gates-doctor of the world
To read the original version of the interview, see DOCUMENT 7
To read an excerpt translated into English, see DOCUMENT 8
In 2015, Bill Gates sounded the alarm at a press conference that will go viral: nearly 30 million people have watched it to date. It describes the catastrophic scenario that the entire planet has experienced since the start of the Covid-19 epidemic
It’s easy to predict a pandemic when you start it
To read the full article see DOCUMENT 9
To read the full articles see DOCUMENTS 10 et 11
TREATMENT OF COVID-19 VIRAL INFECTION WITH HYDROXYCHLOROQUINE
Justification for the use of:
– Hydroxychloroquine
– Hydroxychloroquine and Azithromycin (or an antibiotic from the family of macrolides or tetracyclines):
To read the full article see DOCUMENT 20 (USB Key)
To read the full article see DOCUMENT 22 (USB Key)
1-Unité de Parasitologie. Département d’infectiologie de terrain, Institut de Recherche Biomédicale des Armées, Marseille, France. 2-Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, UM 63, CNRS 7278, IRD 198, Inserm 1095, Aix Marseille Université, Marseille, France. 3-Fédération des Laboratoires, Hôpital d’Instruction des Armées Sainte Anne, Toulon, France. 4-Equipe Résidente de Recherche en Infectiologie Tropicale, Institut de Recherche Biomédicale des Armées, Marseille, France. 5-Centre National de Référence du Paludisme, Marseille, France. 6-Unité de Parasitologie et d’Entomologie, Département des
Maladies Infectieuses, , Institut de Recherche Biomédicale des Armées, Brétigny sur Orge, France.
Why Agnès BUZYN and Olivier VERAN have banned the prescription
of Hydroxychloroquine
to Covid-19 infected people ?
Agnès BUZYN and Yves LEVY know that DNA fragments from the germ of Malaria are inserted into the genome of Covid-19(see DOCUMENT 2)
Under these conditions, administration of hydroxychloroquine destroys the genome of Covid-19 and stops the infection.
WARNING
– Covid-19 helped spark a false pandemic, and spread fear across the world, to make us accept the Covid-19 vaccine.
– By seeking to vaccinate the entire world population, the sponsors of this vaccine, Bill Gates and his allies, want to enslave and control us, pursuing two objectives:
– Control the entire world population after having vaccinated it, thanks to the deployment of 5G; – Limit the world’s population.
This vaccine is very dangerous because it will cause, in vaccinated people, deleterious immunodeficiency, due, in particular, to the HIV sequences of its genome.
MEN WORLDWIDE MUST REFUSE COVID-19 VACCINE THAT BILL GATES AND ITS ALLIES WANT TO IMPOSE ON US